Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Accelerating identification and regulatory approval of investigational cancer drugs.

Esserman LJ, Woodcock J.

JAMA. 2011 Dec 21;306(23):2608-9. doi: 10.1001/jama.2011.1837. No abstract available.

PMID:
22187281
2.

Translation of cancer immunotherapies.

Mulé JJ, Weber JS.

Nat Med. 2004 Nov;10(11):1153; author reply 1153-4. No abstract available.

PMID:
15516900
3.

Competitors try collaboration to speed drug development.

Patlak M.

J Natl Cancer Inst. 2010 Jun 16;102(12):841-3. doi: 10.1093/jnci/djq227. Epub 2010 Jun 8. No abstract available.

PMID:
20530762
4.

Uneasy alliance--clinical investigators and the pharmaceutical industry.

Bodenheimer T.

N Engl J Med. 2000 May 18;342(20):1539-44. No abstract available.

PMID:
10816196
5.

Seamless Oncology-Drug Development.

Prowell TM, Theoret MR, Pazdur R.

N Engl J Med. 2016 May 26;374(21):2001-3. doi: 10.1056/NEJMp1603747. Epub 2016 Apr 13. No abstract available.

6.

Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation.

Davis C, Abraham J.

Sociol Health Illn. 2011 Jul;33(5):731-47. doi: 10.1111/j.1467-9566.2010.01310.x. Epub 2011 Feb 11.

7.

Working together to enhance the efficiency of medical product development.

Sanhai WR.

J Nucl Med. 2008 Jun;49(6):43N-45N. No abstract available.

8.

The seamless approach to drug development in oncology.

Pazdur R.

Clin Adv Hematol Oncol. 2016 Dec;14(12):958-959. No abstract available.

PMID:
28212356
9.

Can single-patient investigational new drug studies hurry slow trains to the fast track?

Chenoweth D.

Drug Discov Today. 2006 Mar;11(5-6):185-6.

PMID:
16580594
10.

The FDA critical path initiative and its influence on new drug development.

Woodcock J, Woosley R.

Annu Rev Med. 2008;59:1-12. doi: 10.1146/annurev.med.59.090506.155819. Review.

PMID:
18186700
11.

Looking for solid ground along the Critical Path.

Ratner M.

Nat Biotechnol. 2006 Aug;24(8):885-7. Epub 2006 Aug 3. No abstract available.

PMID:
16900118
12.

Drug and vaccine development for infectious diseases: the value of priority review vouchers.

Matheny J, Smith B, Courtney B, Mair M.

Clin Pharmacol Ther. 2009 Jun;85(6):571-2. doi: 10.1038/clpt.2009.53. No abstract available.

PMID:
19451907
13.

New office and new leader aim to streamline FDA cancer drug review process.

Twombly R.

J Natl Cancer Inst. 2005 May 18;97(10):708-9. No abstract available.

PMID:
15900036
14.

Approval may embolden industry to combine cancer therapies.

Deng B.

Nat Med. 2015 Feb;21(2):105. doi: 10.1038/nm0215-105. No abstract available.

PMID:
25654594
15.

Accelerated approval seen as triumph and roadblock for cancer drugs.

Susman E.

J Natl Cancer Inst. 2004 Oct 20;96(20):1495-6. No abstract available.

PMID:
15494596
16.

A critical tipping point.

Zuckerman MB.

US News World Rep. 2002 Apr 22;132(13):72. No abstract available.

PMID:
11993366
17.

Accelerated approval regulations may need overhaul, panel suggests.

Finkelstein JB.

J Natl Cancer Inst. 2005 Dec 21;97(24):1802-4. No abstract available.

PMID:
16368938
18.

Pharmacogenomics. Going from genome to pill.

Service RF.

Science. 2005 Jun 24;308(5730):1858-60. No abstract available.

PMID:
15976283
19.

Paving roads for new drugs in oncology.

Zaenker KS, Entschladen F.

Recent Pat Anticancer Drug Discov. 2009 Jun;4(2):137-45. Review.

PMID:
19519536
20.

Oncology's first Phase 0 trial.

Rowan K.

J Natl Cancer Inst. 2009 Jul 15;101(14):978-9. doi: 10.1093/jnci/djp213. Epub 2009 Jul 7. No abstract available.

PMID:
19584322

Supplemental Content

Support Center